DGAP-News: ERYTECH successfully raises EUR30 million for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: ERYTECH successfully raises EUR30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

DGAP-News: ERYTECH PHARMA SA / Key word(s): Capital Increase ERYTECH successfully raises EUR30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments 23.10.2014 / 12:30 --------------------------------------------------------------------- ERYTECH successfully raises EUR30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments - Reserved capital increased with EUR30 million, of which 68% subscribed by US investors specialized in life sciences - Following its recent success in acute leukemia, ERYTECH intends to speed up its development in the USA and in solid Tumors Lyon, France, October 23, 2014 - ERYTECH (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical need, announces today the successful completion of a capital increase for a total amount of EUR30 million. Gil Beyen, Chairman & CEO of ERYTECH, comments: "Following the good Phase III results of our clinical study on GRASPA(R) in acute lymphoblastic leukemia, the strategy of ERYTECH Pharma is to further increase the potential of this product toward other indications such as lymphomas and solid tumors and speed up its development in the US. This successful capital increase operation has allowed us to establish the financial basis for this growth strategy while further expanding our shareholder base in the US, the reference market for our sector." Modalities of the operation A total of 1,224,489 new shares will be issued within a capital increase with suppression of preferential subscription rights, reserved for investors accustomed to investing in the health sector. The new shares represent around 17.8% of the number of shares in circulation (after capital increase). The issue price has been set at EUR24.50 per share, in accordance with resolution 10 of the Shareholders' Meeting of June 17, 2014. This price represents a discount of 3.5% compared to the weighted average stock price over the past five trading sessions, which was EUR25.39. In total, 80% of the operation was executed internationally, with 68% in the U.S. Use of proceeds The proceeds from the issue are to be used by the company as additional means for financing of: - two new Phase II or Phase III clinical studies on ERY-ASP(TM)/GRASPA(R) in oncology or hemato-oncology; - the acceleration of the development of the clinical Phase I/II study with ERY-ASP(TM)/GRASPA(R) and an additional clinical study in the U.S.; - the pre-clinical and Phase I clinical development of ERY-MET in a therapeutic indication in oncology and the pharmaceutical production of GMP batches of methioninase (in addition to Bpifrance financing); - the regulatory and clinical costs for registering ERY-ASP(TM)/GRASPA(R) in Europe; - the general costs associated with the completion of the above projects. The cost of the planned clinical studies has been estimated based on the experience acquired by ERYTECH from conducting various clinical studies with ERY-ASP(TM)/GRASPA(R) in acute lymphoblastic leukemia, acute myeloid leukemia and pancreatic cancer, and will be in the order of the studies that have already been completed. Furthermore, ERYTECH will use the proceeds of this capital increase to finance its share, 52%, of the future costs for ERY-MET with the knowledge that Bpifrance will assume 48% of the project costs as defined in the contract. The Company's current cash position and this additional financing will enable it to see the above-mentioned projects through to their end. Third quarter revenues and cash position on September 30, 2014 On September 30, 2014, the cash and cash equivalents amounted to 10.0 million euros compared to 12.3 million euros on June 30, 2014. When including the net proceeds of this financing, the cash position on October 23, 2014 amounts to approximately 38 million euros. During the third quarter of 2014, ERYTECH Pharma did not report any income from activities. This financial information as of September 30, 2014 has been communicated in lieu of the quarterly communication initially planned for November 4, 2014. Listing of the new shares The new shares have a nominal value of EUR122,449 and will be in the same category as the company's current shares. They will carry immediate dividend rights and will give the right, as of their issue, to all distributions decided by the Company as of this date. Listing on the Euronext regulated market ("Euronext Paris") will be requested and will be subject to a listing prospectus and the approval of the French Autorité des Marchés Financiers (AMF). The new shares will be listed under the same code as the previous shares (ISIN FR0011471135). The settlement and delivery should occur on October 27, 2014. Lock-up agreement - shareholders Upon this issue, the Company has agreed not to issue new shares for a period of 90 days after the date of settlement and delivery, subject to the usual exceptions. For reference, the issue affects the allocation of capital and voting rights of the Company (as of October 17, 2014) as follows: <pre> Situation before capital Situation after capital increase on the basis of increase before the capital structure on settlement/delivery October 17 2014 Shareholders Number of % of % of Number of % of % of shares capital voting shares capital voting Management 603 290 10,66% 16,37% 603 290 8,77% 13,77% Idinvest 813 400 14,38% 11,01% 813 400 10,64% 9,53% Auriga Partners 1 018 212 18,00% 25,09% 1 018 212 14,79% 21,39% Recordati Orphan 431 034 7,62% 6,08% 431 034 6,26% 5,18% Drugs Other shareholders 90 584 1,59% 2,17% 90 584 1,32% 1,85% < 0,5% Bearer shares 2 701 752 43,47% 39,23% 3 926 241 57,04% 47,21% TOTAL 5 658 272 100,00% 100,00% 6 882 761 100 % 100% </pre> The transaction was lead by Bryan Garnier as Global Coordinator and LifeSci Capital as placement agent in the U.S. "This operation confirms the strong appeal of ERYTECH to international investors, particularly with specialized American health care funds. The extensions of the therapeutic indications for ERY-ASP(TM)/GRASPA(R), the acceleration of our developments in the U.S. and the new drug candidate ERY-MET will contribute to the growth of the strategic value of our technology and our oncology product portfolio," says Gil Beyen, Chairman & CEO of ERYTECH Pharma. Information available to the public Copies of the Reference Document registered by the AMF on June 4, 2014 under the number R.14.038 are available free of charge at the headquarters of ERYTECH Pharma, 60 Avenue Rockefeller, Bâtiment Adénine, Lyon, France, and on the websites of ERYTECH Pharma (www.erytech.com) and the AMF (www.amf-france.org). ERYTECH Pharma would like to refer investors to Chapter 4 'Risk Factors' in the Reference Document and to Chapter 6 'Risk Factors' in the Document de Base. About ERYTECH and ERYASP(TM)/GRASPA(R): www.erytech.com Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA(R), an original and effective treatment that destroys cancerous cells through "starvation" while significantly reducing side effects. ERY-ASP/GRASPA(R) is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) in Europe and is in Phase IIb in Acute Myeloid Leukemia (AML). The product is also in Phase I/II in ALL in the U.S. Every year about 50,000 patients are diagnosed with ALL or AML in Europe and the U.S. Today, about 80% of these patients, mainly relapsing adults and children, cannot use the current forms of asparaginase due to their toxicity. ERY-ASP is being developed with the goal of improving the tolerability profile in order to treat all patients diagnosed with acute leukemia, even the most fragile ones. The market segment addressed by ERYTECH represents a potential of 1 billion euros. The Company is also developing treatments for solid tumors and some orphan indications outside oncology. It is currently conducting a Phase II study on pancreatic cancer in Europe and examining other solid tumor indications for ERY-ASP. The Company has obtained orphan drug designations for ERY-ASP/GRASPA(R) in ALL, AML and pancreatic cancer in Europe and the U.S. It has its own operational manufacturing sites in Lyon, France and Philadelphia in the U.S. ERYTECH has concluded two distribution partnership agreements, one in Europe with Orphan Europe (Recordati Group), one of the main actors in orphan drugs, and the other in Israel with the TEVA Group. ERYTECH is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker code: ERYP) and is part of the CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable and Next Biotech indexes. ERYTECH shares are eligible to PEA-PME (French share savings plan for SMEs). Contacts <pre> ERYTECH NewCap Gil Beyen Julien Perez & Emmanuel Huynh Chairman and Chief Executive Officer Investor Relations Pierre-Olivier Goineau Nicolas Mérigeau Vice President, Chief Operating Officer Press Contact Tel.: +33 4 78 74 44 38 Tel.: +33 1 44 71 98 52 investors@erytech.com erytech@newcap.fr </pre> Warning This press release is for information purposes only and does not constitute and shall not be considered as constituting a public offer by ERYTECH Pharma, an offer to purchase or as an intention to solicit the interest of the public for an offering of any kind whatsoever in any country including France. This shares discussed in this press release may not and shall not be publicly offered in France except to natural or legal persons investing in shares in the usual manner in the health sector. This press release does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular by Directive 2010/73/EC, to the extent such Directive has been transposed in the relevant member State of the European Economic Area (the "Prospectus Directive"). With respect to the member States of the European Economic Area which have implemented the Prospectus Directive, no action has been undertaken or will be undertaken to make an offer to the public of the securities requiring a publication of a prospectus in any member State. As a result, the shares of ERYTECH may not be offered and will not be offered in any member State except, pursuant to the exemptions described in article 3(2) of the Prospectus Directive, if they have been transposed by this member State or in any other circumstances not requiring ERYTECH Pharma to publish a prospectus as provided under article 3(2) of the Prospectus Directive and/or regulations applicable in this member State. This press release and the information it contains do not constitute an offer to subscribe or solicitation to purchase or subscribe for ERYTECH Pharma securities in the United States or in any jurisdiction in which the operation could be subject to restrictions. The shares or any other securities of ERYTECH Pharma may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or exempt from registration. The shares of ERYTECH Pharma have not been and will not be registered under the U.S. Securities Act and ERYTECH Pharma does not intend to make any public offer of its shares in the United States. In the United Kingdom, this press release is addressed to and intended solely to persons who are "qualified investors" within the meaning of Article 2(1)(e) (i), (ii) ou (iii) of the Directive Prospectus of the European Union and who are also considered (i) "investment professionals" (individuals with professional investment experience) within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) persons entering the field of application of Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) persons who have received an invitation or call to participate in an investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) for the issue or sale of financial securities could be legally addressed (all of these individuals are collectively referred to as the "Relevant Persons"). In the United Kingdom, this document is solely intended to relevant persons and no other person other than a concerned person may use or refer to this document. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons. In accordance with Article 211-3 of the AMF General Regulations, please note that: - the issue does not give rise to the establishment of a Prospectus subject to the approval of the AMF. On the other hand, the listing of the shares to be issue within the scope of the operation shall give rise to the establishment of a Prospectus approved by the AMF. - Shares thus subscribed or acquired may only be distributed to the public, directly or indirectly, under the conditions specified in articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the monetary and financial code. The distribution of this press release in certain countries may be subject to specific regulations. The persons in possession of this press release shall then get knowledge of any local restrictions and shall comply with these restrictions. Any decision to subscribe to shares of ERYTECH Pharma must be made only on the basis of public information on ERYTECH Pharma. --------------------------------------------------------------------- 23.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 292988 23.10.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 51

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 222

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 69

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 197

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell plc Announces Strategic Share Buybacks Amid Market Moves

Updated Category News Views 250

Shell plc Engages in Significant Share Buybacks Transaction in Own Shares Shell plc, a global leader in energy and petrochemical sectors, has undertaken a strategic initiative involving the purchase of its own shares for cancellation to optimize its capital structure. This decision aligns with the company’s broader strategy to enhance shareholder value through various...

Continue Reading
CSL Seqirus Strengthens Pandemic Readiness with New BARDA Award

Updated Category News Views 280

CSL Seqirus Receives Significant BARDA Award CSL Seqirus has recently received a noteworthy award from the Biomedical Advanced Research and Development Authority (BARDA). This grant is aimed at furthering the company's capabilities in preparing for potential pandemic situations through the development of avian influenza vaccines. The need for preparedness in public health...

Continue Reading
Navient’s Third Quarter Results: Financial Performance Insights

Updated Category News Views 86

Navient Announces Third Quarter 2024 Financial Results HERNDON, Va. — Navient (Nasdaq: NAVI) shared its third quarter financial results for 2024, showcasing the company’s ongoing commitment to providing innovative financial services and solutions. The comprehensive financial results are listed on the company's official site, ensuring transparency and accessibility for...

Continue Reading
Comstock Inc. Unveils Insights from 3Q24 Stakeholder Analysis

Updated Category News Views 169

Comstock Inc. (NYSE: LODE) dropped its Q3 2024 Stakeholder Perception Analysis Report, and you know how these things go—traders squinted at the numbers while trying to decipher what the hell it meant for their investments. So here's the deal: Comstock put out this report to show how its stakeholders felt about its performance and strategy, but really, it raised more...

Continue Reading
GraniteShares Unveils Innovative YieldBOOST Fund-of-Funds ETFs

Updated Category News Views 370

GraniteShares Introduces Unique Fund-of-Funds ETFs GraniteShares, an innovative leader in the ETF space, has recently introduced two new YieldBOOST Fund-of-Funds ETFs. These expansions reflect their commitment to offering cutting-edge investment solutions that cater to the evolving needs of investors. What Are the New ETFs? The two new offerings are the GraniteShares...

Continue Reading